Medtronic has reported that its Mosaic bioprosthetic heart valve has demonstrated positive performance results after 12 years in a study published in The Journal of Thoracic and Cardiovascular Surgery.
The porcine bioprosthesis was evaluated in 1,029 patients who underwent aortic valve replacement and mitral valve replacement between 1994 and 2000.
The 12-year follow-up results of the study revealed that the valve was free from structural deterioration in 93.3% of aortic valve replacement patients aged 60 years and older and in 95.3% of mitral valve replacement patients aged 70 years and older.
Additionally, haemodynamic performance data showed stability up to ten years.
The valve, approved by the US Food and Drug Administration (FDA) in 2000, is an artificial heart valve used to replace a diseased or damaged natural valves.
Related Companies
